Dasatinib plus quercetin

updated

What is Dasatinib plus quercetin?

Dasatinib plus quercetin (D+Q) is two separate agents, not one product. Dasatinib is an FDA-approved prescription kinase inhibitor for Philadelphia chromosome-positive leukemia, first approved in 2006, and quercetin is a flavonol supplement. The combination is not approved for any use, and nothing in the dasatinib label covers senescence or aging.

Dasatinib plus quercetin (D+Q) pairs a prescription leukemia drug with the supplement quercetin and is used off label as a senolytic. Dasatinib is FDA-approved for Philadelphia chromosome-positive leukemia, but its label safety data come from continuous cancer dosing and do not transfer to short senolytic courses, and the combination is not approved for any use. Human evidence is small and mixed: a 9-person open-label biopsy study showed fewer senescent cell markers, a bone trial missed its primary endpoint, and a 31-person fatty liver trial reported benefit that is unreplicated.

Kinase inhibitor plus flavonol, used as a senolytic

  • Dasatinib is FDA-approved for Philadelphia chromosome-positive leukemia (SPRYCEL, first approved 28 June 2006); nothing in its label covers senescence or aging, and no combined D+Q product exists.
  • The SPRYCEL label's safety rates come from leukemia patients on continuous daily dosing and do not carry over to short intermittent senolytic courses.
  • In 9 people with diabetic kidney disease, biopsies 11 days after a short D+Q course showed fewer senescent cell markers; there was no control group.
  • In a phase 2 trial of 60 postmenopausal women, D+Q did not change the primary endpoint, CTX at 20 weeks (median -4.1% versus -7.7% in control; P = 0.611).
  • In a 31-person fibrotic MASH trial, fibrosis improved in 47% on D+Q versus 7% on placebo (P = 0.02), with adverse events in 82% versus 43%; it is online ahead of print and unreplicated.
  • A PubMed search on 11 October 2026 found no randomized trial of D+Q in healthy adults reporting a hard aging outcome.

What is dasatinib plus quercetin, and what is approved?

Dasatinib plus quercetin (D+Q) is two separate agents, not one product. Dasatinib is an FDA-approved prescription kinase inhibitor for Philadelphia chromosome-positive leukemia, first approved in 2006, and quercetin is a flavonol supplement. The combination is not approved for any use, and nothing in the dasatinib label covers senescence or aging.

There is no combined product. Dasatinib (PubChem CID 3062316, C22H26ClN7O2S, 488.0 g/mol, CAS 302962-49-8; Sprycel is among its synonyms) is a prescription kinase inhibitor. Quercetin (CID 5280343, C15H10O7, 302.23 g/mol, CAS 117-39-5) is a flavonol taken as a supplement. Trial quercetin products and amounts vary, including a phytosome product, so doses and products do not transfer between studies. This page gives no dosing schedule for the combination.

FDA first approved SPRYCEL under NDA 021986 on 28 June 2006 (Bristol Myers Squibb). A later application, PHYRAGO, is NDA 216099 with an original approval date of 5 December 2023, and several generic dasatinib applications are listed. The SPRYCEL label (version 49, effective 15 September 2026) covers adults with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase, adults with chronic, accelerated or blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib, adults with Ph+ acute lymphoblastic leukemia (ALL) with resistance or intolerance to prior therapy, and pediatric patients 1 year and older with Ph+ CML in chronic phase or newly diagnosed Ph+ ALL with chemotherapy.

Nothing in the label covers senescence or aging, so use of dasatinib for senescence is outside its labeled indications. The combination is not approved for any use. On 11 October 2026, an openFDA Drugs@FDA query for quercetin returned no match, and a DailyMed drug-name search returned only homeopathic and similar multi-ingredient listings that contain quercetin, with no single-ingredient quercetin drug label.

PubChem: dasatinib and quercetin are two separate agents; no combined product

Chemical identity record

National Library of Medicine. PubChem compound records CID 3062316 (dasatinib) and CID 5280343 (quercetin). openFDA Drugs@FDA and DailyMed drug-name searches for quercetin run on 11 October 2026.

Dasatinib: PubChem CID 3062316, C22H26ClN7O2S, 488.0 g/mol, CAS 302962-49-8, with Sprycel among the listed synonyms. Quercetin: CID 5280343, C15H10O7, 302.23 g/mol, CAS 117-39-5. There is no combined product: dasatinib is a prescription kinase inhibitor and quercetin is a flavonol taken as a supplement. Trial quercetin products and amounts vary, including a phytosome product, so doses and products do not transfer between studies. On 11 October 2026 an openFDA Drugs@FDA query for quercetin returned no match, and a DailyMed drug-name search returned only homeopathic and similar multi-ingredient listings that contain quercetin, with no single-ingredient quercetin drug label.

Participants / model
Chemical identity, not a clinical population
Treatment
Defined molecules; separate products
Follow-up
Searches run on 11 October 2026
Study design
NLM chemical records plus dated US approval-record search
Funding
not stated in the source

Identity records only; they say nothing about efficacy or safety.

Read the original source
SPRYCEL label, version 49 effective 15 September 2026: leukemia indications, warnings, PK

FDA prescribing information

DailyMed, U.S. National Library of Medicine. SPRYCEL (dasatinib) oral tablets, prescribing information, label version 49 effective 15 September 2026. Set ID 4764f37b-c9e6-4ede-bcc2-8a03b7c521df. The quercetin safety statements come from a German risk-assessment review (Andres 2018, PMID 29127724).

The label covers adults with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase, adults with chronic, accelerated or blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib, adults with Ph+ acute lymphoblastic leukemia (ALL) with resistance or intolerance to prior therapy, and pediatric patients 1 year and older with Ph+ CML in chronic phase or newly diagnosed Ph+ ALL with chemotherapy. Nothing in the label covers senescence or aging. The label lists no contraindications and warns of myelosuppression, bleeding (Grade 3 or 4 hemorrhage in 5.8% of adults, Grade 5 in 0.4%), fluid retention including pleural effusion (Grade 3 or 4 in 6% of adults with chronic phase CML on the labeled regimen, n = 548), cardiovascular toxicity (cardiac ischemic events 3.9% on dasatinib versus 1.6% on imatinib after 5 years in a newly diagnosed CML trial, n = 258), pulmonary arterial hypertension (stop if confirmed), QT prolongation, severe dermatologic reactions, tumor lysis, embryo-fetal toxicity and hepatotoxicity. The most common adverse reactions as a single agent (15% or more) were myelosuppression, fluid retention, diarrhea, headache, rash, hemorrhage, dyspnea, fatigue, nausea and musculoskeletal pain. Mean terminal half-life is 3 to 5 hours, metabolism is mainly CYP3A4 (avoid strong inhibitors and grapefruit juice), and the label says not to give H2 antagonists or proton pump inhibitors with it. These rates come from leukemia patients on daily dosing; senolytic trials use short intermittent courses, so the label rates do not carry over to those regimens. For quercetin, a German risk-assessment review found adverse effects rarely reported and mild in human studies, but no adequate data on long-term use (over 12 weeks) at intakes of 1000 mg or more, and animal signals for worsening damaged kidneys and promoting estrogen-dependent tumors, plus drug interactions.

Participants / model
Adults and children with Ph+ CML or Ph+ ALL in label studies; humans and animals in the quercetin review
Treatment
SPRYCEL oral tablets (dasatinib alone), continuous dosing in cancer; supplemental quercetin in the review
Follow-up
Label version effective 15 September 2026
Study design
FDA prescribing information plus a risk-assessment review
Funding
not stated in the source

The label covers dasatinib alone in leukemia. Its safety rates come from continuous daily dosing and do not transfer to short senolytic courses. The quercetin statements come from the review, not the label.

Read the original source
Drugs@FDA: SPRYCEL approved 28 June 2006; PHYRAGO original approval 5 December 2023

Regulatory record

U.S. Food and Drug Administration. Drugs@FDA application record for NDA 021986 (SPRYCEL), with related dasatinib application NDA 216099 (PHYRAGO). Dates read from the openFDA Drugs@FDA records.

FDA first approved SPRYCEL under NDA 021986 on 28 June 2006 (Bristol Myers Squibb). A later application, PHYRAGO, is NDA 216099 with an original approval date of 5 December 2023, and several generic dasatinib applications are listed.

Participants / model
Not a clinical population
Treatment
Drug applications
Follow-up
Approvals from 2006 to 2023
Study design
FDA application records
Funding
not stated in the source

These records give approval dates. Indications come from the product label.

Read the original source

Where does the senolytic claim come from?

From mouse and tissue-explant work. Transplanted senescent cells made young mice dysfunctional, D+Q lowered senescent cells and frailty-related cytokines in human adipose tissue explants, and intermittent oral senolytics relieved dysfunction and increased survival in mice. No living humans were studied.

Transplanting small numbers of senescent cells into young mice caused persistent physical dysfunction and shortened survival. D+Q lowered the number of naturally occurring senescent cells and their secretion of frailty-related cytokines in explants of human adipose tissue.

Intermittent oral senolytics given to senescent-cell-transplanted young mice and to naturally aged mice relieved physical dysfunction and increased post-treatment survival by 36%, with the mortality hazard cut to 65%. Several authors hold a financial interest, including patents on senolytic drugs.

The work used mice and human tissue explants. No living humans were studied, and the dose given to the mice is not stated in the source.

Origin of the claim: mice and human adipose explants, no living humans

Animal study

Xu M et al. Nat Med. 2018;24(8):1246-1256. PMID 29988130.

Transplanting small numbers of senescent cells into young mice caused persistent physical dysfunction and shortened survival. D+Q lowered the number of naturally occurring senescent cells and their secretion of frailty-related cytokines in explants of human adipose tissue. Intermittent oral senolytics given to senescent-cell-transplanted young mice and to naturally aged mice relieved physical dysfunction and increased post-treatment survival by 36%, with the mortality hazard cut to 65%.

Participants / model
Mice (young, old and senescent-cell-transplanted) and human adipose tissue explants; no living humans
Treatment
Intermittent oral dasatinib plus quercetin in mice, and explant exposure; dose not stated in the source
Follow-up
Intermittent; schedule not stated in the source
Study design
Animal and ex vivo study
Funding
not stated in the source; several authors hold a financial interest, including patents on senolytic drugs

Mouse and explant findings only. They cannot be read as an effect in people.

Read the original source

What did the first human studies and the bone trial find?

The only direct human senescent-cell result is a 9-person open-label study with no control group, in which biopsies showed fewer senescent cell markers 11 days after treatment. The randomized bone trial in 60 postmenopausal women missed its primary endpoint (CTX at 20 weeks, P = 0.611).

In 9 people with diabetic kidney disease (mean age 68.7 years, 2 women) given a short oral course of D+Q, adipose tissue and skin biopsies taken before and 11 days after treatment showed fewer p16INK4A and p21CIP1-expressing cells, fewer cells with senescence-associated beta-galactosidase activity, fewer adipose macrophages, and lower circulating IL-1 alpha, IL-6, MMP-9 and MMP-12. There was no control group (NCT02848131).

The authors state that to date no peer-reviewed study had directly shown senolytics decrease senescent cells in humans before this report. Mayo Clinic holds patents on senolytic drugs, and an erratum was published in 2020. This is the only direct human senescent-cell result found, and it is tiny and open-label.

In a phase 2 randomized trial of 60 postmenopausal women, intermittent D+Q did not change the primary endpoint, the bone resorption marker CTX at 20 weeks (median -4.1% on D+Q versus -7.7% in control; P = 0.611). The bone formation marker P1NP rose 16% relative to control at 2 weeks (P = 0.020) and at 4 weeks (P = 0.024) but was not different at 20 weeks, and no serious adverse events were observed. An exploratory subgroup with high T cell p16 mRNA showed a +2.7% radius bone mineral density change (P = 0.004).

The registry (NCT04313634) enrolled 74 women, including a fisetin arm, with a no-intervention control and open-label masking. Authors with patents on senolytics are listed.

9 people with diabetic kidney disease: fewer senescent cell markers, no control group

Clinical trial

Hickson LJ et al. EBioMedicine. 2019;47:446-456. PMID 31542391.

In 9 people with diabetic kidney disease (mean age 68.7 years, 2 women) given a short oral course of dasatinib plus quercetin, adipose tissue and skin biopsies taken before and 11 days after treatment showed fewer p16INK4A and p21CIP1-expressing cells, fewer cells with senescence-associated beta-galactosidase activity, fewer adipose macrophages, and lower circulating IL-1 alpha, IL-6, MMP-9 and MMP-12. There was no control group. The authors state that to date no peer-reviewed study had directly shown senolytics decrease senescent cells in humans before this report.

Participants / model
9 adults with diabetic kidney disease (mean age 68.7 years, 2 women; mean eGFR 27.0 mL/min/1.73 m2)
Treatment
Short oral course of dasatinib plus quercetin; doses and schedule not given on this page
Follow-up
Biopsies before and 11 days after treatment
Study design
Open-label phase 1 pilot with no control group (NCT02848131)
Funding
not stated in the source; Mayo Clinic holds patents on senolytic drugs, and an erratum was published in 2020

Nine people, open-label, no control: a biomarker signal, not an outcome result.

Read the original source
Bone: 60 postmenopausal women, 20 weeks, primary endpoint not met

Randomized controlled trial

Farr JN et al. Nat Med. 2024;30(9):2605-2612. PMID 38956196.

In this phase 2 randomized trial of 60 postmenopausal women, intermittent D+Q did not change the primary endpoint, the bone resorption marker CTX at 20 weeks (median -4.1% on D+Q versus -7.7% in control; P = 0.611). The bone formation marker P1NP rose 16% relative to control at 2 weeks (P = 0.020) and at 4 weeks (P = 0.024) but was not different at 20 weeks, no serious adverse events were observed, and an exploratory subgroup with high T cell p16 mRNA showed a +2.7% radius bone mineral density change (P = 0.004). The registry describes a no-intervention control and open-label masking, and posts other adverse events in 23 of 30 on D+Q versus 5 of 30 controls (registry-posted, not peer reviewed).

Participants / model
60 postmenopausal women (the registry enrolled 74, including a fisetin arm)
Treatment
Oral dasatinib plus quercetin on an intermittent schedule over 20 weeks, versus no intervention; doses not given on this page
Follow-up
20 weeks
Study design
Phase 2 randomized open-label trial with a no-intervention control (NCT04313634)
Funding
not stated in the source; authors with patents on senolytics are listed

The adverse-event comparison from the registry is open-label with no placebo, and registry-posted figures are not peer reviewed.

Read the original source

What did the lung fibrosis and Alzheimer's disease pilots find?

Both were small pilots. In idiopathic pulmonary fibrosis, an open-label pilot of 14 patients improved on walking and chair-stand tests, but a randomized pilot of 12 found no meaningful difference between groups. In Alzheimer's disease, two pilots of 5 and 12 people showed feasibility only, with no appropriate control group.

In an open-label pilot of 14 patients with idiopathic pulmonary fibrosis given D+Q in short intermittent courses, retention was 100%, one serious adverse event was reported, and 6-minute walk distance, gait speed and chair-stand time improved (p < .05) while pulmonary function was unchanged (NCT02874989).

In the follow-up randomized placebo-controlled pilot of 12 patients, all doses were taken, no serious adverse event was related to D+Q, and physical, pulmonary and frailty measures did not appear to differ meaningfully between groups, though the pilot was under-powered. The abstract states the placebo arm reported fewer overall non-serious adverse events (65 versus 22), and sleep disturbances and anxiety occurred in 4 of 6 on D+Q versus 0 of 6 on placebo. Mayo-linked authors hold senolytic patents.

In 5 people with early symptomatic Alzheimer's disease who completed 12 weeks of D+Q, dasatinib reached cerebrospinal fluid in 4 of 5 (CSF to plasma ratio 0.422 to 0.919%) while quercetin was not detected, the treatment was well tolerated, and cognitive and imaging endpoints did not differ from baseline.

In 12 older adults at risk of Alzheimer's disease who completed the study (about 10% of telephone-screened people completed), intermittent D+Q over 12 weeks produced no related serious adverse events and a non-significant MoCA change of +1.0 point (95% CI -0.7 to 2.7). The authors state there was no appropriate control group and the data are preliminary.

Lung fibrosis: 14-patient open-label pilot, then a 12-patient randomized pilot with no meaningful difference

Randomized controlled trial

Nambiar A et al. EBioMedicine. 2023;90:104481. PMID 36857968.

In an open-label pilot of 14 patients with idiopathic pulmonary fibrosis given dasatinib plus quercetin in short intermittent courses, retention was 100%, one serious adverse event was reported, and 6-minute walk distance, gait speed and chair-stand time improved (p < .05) while pulmonary function was unchanged. In the follow-up randomized placebo-controlled pilot of 12 patients, all doses were taken, no serious adverse event was related to D+Q, physical, pulmonary and frailty measures did not appear to differ meaningfully between groups (under-powered), the abstract states the placebo arm reported fewer overall non-serious adverse events (65 versus 22), and sleep disturbances and anxiety occurred in 4 of 6 on D+Q versus 0 of 6 on placebo.

Participants / model
14 patients with idiopathic pulmonary fibrosis (open-label); 12 patients with idiopathic pulmonary fibrosis aged over 50 (randomized)
Treatment
Oral dasatinib plus quercetin in short intermittent courses over a few weeks; doses and schedule not given on this page
Follow-up
A few weeks of intermittent courses
Study design
Open-label pilot and randomized placebo-controlled pilot
Funding
not stated in the source; Mayo-linked authors hold senolytic patents

The randomized pilot was under-powered, and its adverse-event counts favor placebo.

Read the original source
Alzheimer's pilots: 5 and 12 people, feasibility only, no appropriate control group

Clinical trial

Gonzales MM et al. Nat Med. 2023;29(10):2481-2488. PMID 37679434.

In 5 people with early symptomatic Alzheimer's disease who completed 12 weeks of D+Q, dasatinib reached cerebrospinal fluid in 4 of 5 (CSF to plasma ratio 0.422 to 0.919%) while quercetin was not detected, the treatment was well tolerated, and cognitive and imaging endpoints did not differ from baseline. In 12 older adults at risk of Alzheimer's disease who completed the study (about 10% of telephone-screened people completed), intermittent dasatinib plus quercetin over 12 weeks produced no related serious adverse events and a non-significant MoCA change of +1.0 point (95% CI -0.7 to 2.7); the authors state there was no appropriate control group and the data are preliminary.

Participants / model
5 adults with mild Alzheimer's disease; 12 older adults at risk of Alzheimer's disease
Treatment
Oral dasatinib plus quercetin for 12 weeks; doses and schedule not given on this page
Follow-up
12 weeks
Study design
Open-label phase 1 pilots
Funding
not stated in the source

Feasibility and tolerability only. The authors of the second pilot state there was no appropriate control group.

Read the original source

What did the fatty liver trial and the epigenetic-clock pilot find?

The newest randomized result is positive and unreplicated: in 31 people with fibrotic MASH, fibrosis improved in 47% on D+Q versus 7% on placebo (P = 0.02), and the paper is online ahead of print. A separate uncontrolled 19-participant pilot found epigenetic age acceleration rose on some clocks.

A phase 2 double-blind placebo-controlled trial of 31 participants with fibrotic metabolic dysfunction-associated steatohepatitis (MASH; median age 56, 76% male, 58% with type 2 diabetes) gave D+Q or placebo in intermittent cycles. The primary endpoint, at least one stage of fibrosis improvement without MASH worsening on paired biopsies, was met in 47% on D+Q versus 7% on placebo (P = 0.02), and MASH resolution was 53% versus 7% (P = 0.02). Adverse events were more frequent on D+Q (82% versus 43%) but all self-limiting.

The paper is online ahead of print as of 1 October 2026 and has no replication, and the abstract does not give a registry number. An Amsterdam UMC trial with a matching design (NCT05506488, 30 participants) was seen but not matched to it.

Separately, in a phase 1 pilot of 19 participants on D+Q for 6 months, epigenetic age acceleration rose significantly on first-generation and mitotic clocks at 3 and 6 months and telomere length fell, with no significant change on second- and third-generation clocks. A second phase a year later, in which 19 participants (10 from the first phase) took D+Q plus fisetin for 6 months, found only non-significant increases. Several authors are TruDiagnostic employees. The pilot had no control group, and these are biomarker clocks, not aging outcomes.

Fibrotic MASH: 31 randomized, fibrosis improved in 47% versus 7%, online ahead of print

Randomized controlled trial

Koning M et al. Nat Metab. 2026. PMID 42823536.

A phase 2 double-blind placebo-controlled trial of 31 participants with fibrotic metabolic dysfunction-associated steatohepatitis (MASH; median age 56, 76% male, 58% with type 2 diabetes) gave D+Q or placebo in intermittent cycles. The primary endpoint, at least one stage of fibrosis improvement without MASH worsening on paired biopsies, was met in 47% on D+Q versus 7% on placebo (P = 0.02), MASH resolution was 53% versus 7% (P = 0.02), and adverse events were more frequent on D+Q (82% versus 43%) but all self-limiting. Separately, in a phase 1 pilot of 19 participants on a D+Q-based regimen for 6 months, epigenetic age acceleration rose significantly on first-generation and mitotic clocks at 3 and 6 months and telomere length fell, with no significant change on second- and third-generation clocks.

Participants / model
31 adults with fibrotic MASH; 19 participants in an epigenetic-clock pilot
Treatment
Oral dasatinib plus quercetin in intermittent cycles; D+Q for 6 months in the pilot, then D+Q plus fisetin for 6 months in its second phase; doses and schedule not given on this page
Follow-up
Repeated intermittent cycles (MASH trial); 6 months (pilot)
Study design
Phase 2 double-blind placebo-controlled randomized trial, online ahead of print as of 1 October 2026; and an uncontrolled phase 1 pilot
Funding
not stated in the source; several authors of the epigenetic-clock pilot are TruDiagnostic employees

No replication yet, and the abstract does not give a registry number (an Amsterdam UMC trial with matching design, NCT05506488, 30 participants, was seen but not matched). The epigenetic-clock pilot is uncontrolled.

Read the original source

Does D+Q clear senescent cells in people, and does dasatinib's approval carry over to it?

The senolytic part is supported in mice and by one open-label human biopsy study. The known-safety part holds only for dasatinib's cancer-dose label and does not transfer to short intermittent courses in healthy older adults. A PubMed search on 11 October 2026 found no randomized trial of D+Q in healthy adults reporting a hard aging outcome.

Sellers describe D+Q as a senolytic combination that clears senescent cells in people, with a known safety profile because dasatinib is an approved cancer drug. The senolytic part is supported in mice and by one open-label human biopsy study. The safety part holds only for dasatinib's cancer-dose label and does not transfer to intermittent dosing in healthy older adults.

A PubMed search on 11 October 2026 for dasatinib and quercetin with randomized controlled trial or clinical trial as publication type returned 7 records, all reviewed by title: two lung fibrosis trials, three Alzheimer's disease papers, the bone trial and a senescence-biomarker characterization paper. The filter missed the 2026 fatty liver trial and the 2025 cognition pilot, so publication-type counts understate the literature. No record reviewed is a randomized trial of D+Q in healthy adults reporting a hard aging outcome.

A 2026 systematic review of senolytic, senomorphic and anti-ageing trials (Trivedi 2026) included six completed clinical studies, found preliminary functional and biomarker improvements, and concluded the approaches should be considered investigational, with evidence insufficient to establish efficacy or long-term safety.

A ClinicalTrials.gov search on 11 October 2026 with dasatinib AND quercetin as interventions returned 22 studies: 8 completed (3 with posted results), 6 active not recruiting, 3 recruiting, 2 unknown, 1 enrolling by invitation, 1 not yet recruiting and 1 withdrawn. Registered studies without results show that a study was registered, not that it works.

PubMed search, 11 October 2026: 7 records, no healthy-adult hard-outcome trial; 22 registered studies

PubMed search record

PubMed search run on 11 October 2026: dasatinib[tiab] AND quercetin[tiab] AND (randomized controlled trial[pt] OR clinical trial[pt]). 7 records returned. ClinicalTrials.gov search with dasatinib AND quercetin as interventions run the same day. Systematic review: Trivedi 2026, PMID 42834340.

The search returned 7 records, all reviewed by title: two lung fibrosis trials, three Alzheimer's disease papers, the bone trial and a senescence-biomarker characterization paper. The filter missed the 2026 fatty liver trial and the 2025 cognition pilot, so publication-type counts understate the literature. No record reviewed is a randomized trial of D+Q in healthy adults reporting a hard aging outcome. A 2026 systematic review of senolytic, senomorphic and anti-ageing trials (Trivedi 2026, PMID 42834340) included six completed clinical studies, found preliminary functional and biomarker improvements, and concluded the approaches should be considered investigational, with evidence insufficient to establish efficacy or long-term safety. A ClinicalTrials.gov search run on 11 October 2026 with dasatinib AND quercetin as interventions returned 22 studies: 8 completed (3 with posted results), 6 active not recruiting, 3 recruiting, 2 unknown, 1 enrolling by invitation, 1 not yet recruiting and 1 withdrawn.

Participants / model
Records reviewed and registered trials, not a population
Treatment
Not applicable
Follow-up
Search run on 11 October 2026
Study design
Literature search, systematic review and trial registry
Funding
not stated in the source

A search result shows what PubMed returned on that date. It is not proof that no unindexed study exists. Registered studies without results show that a study was registered, not that it works.

Read the original source
SPRYCEL label, version 49 effective 15 September 2026: leukemia indications, warnings, PK

FDA prescribing information

DailyMed, U.S. National Library of Medicine. SPRYCEL (dasatinib) oral tablets, prescribing information, label version 49 effective 15 September 2026. Set ID 4764f37b-c9e6-4ede-bcc2-8a03b7c521df. The quercetin safety statements come from a German risk-assessment review (Andres 2018, PMID 29127724).

The label covers adults with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase, adults with chronic, accelerated or blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib, adults with Ph+ acute lymphoblastic leukemia (ALL) with resistance or intolerance to prior therapy, and pediatric patients 1 year and older with Ph+ CML in chronic phase or newly diagnosed Ph+ ALL with chemotherapy. Nothing in the label covers senescence or aging. The label lists no contraindications and warns of myelosuppression, bleeding (Grade 3 or 4 hemorrhage in 5.8% of adults, Grade 5 in 0.4%), fluid retention including pleural effusion (Grade 3 or 4 in 6% of adults with chronic phase CML on the labeled regimen, n = 548), cardiovascular toxicity (cardiac ischemic events 3.9% on dasatinib versus 1.6% on imatinib after 5 years in a newly diagnosed CML trial, n = 258), pulmonary arterial hypertension (stop if confirmed), QT prolongation, severe dermatologic reactions, tumor lysis, embryo-fetal toxicity and hepatotoxicity. The most common adverse reactions as a single agent (15% or more) were myelosuppression, fluid retention, diarrhea, headache, rash, hemorrhage, dyspnea, fatigue, nausea and musculoskeletal pain. Mean terminal half-life is 3 to 5 hours, metabolism is mainly CYP3A4 (avoid strong inhibitors and grapefruit juice), and the label says not to give H2 antagonists or proton pump inhibitors with it. These rates come from leukemia patients on daily dosing; senolytic trials use short intermittent courses, so the label rates do not carry over to those regimens. For quercetin, a German risk-assessment review found adverse effects rarely reported and mild in human studies, but no adequate data on long-term use (over 12 weeks) at intakes of 1000 mg or more, and animal signals for worsening damaged kidneys and promoting estrogen-dependent tumors, plus drug interactions.

Participants / model
Adults and children with Ph+ CML or Ph+ ALL in label studies; humans and animals in the quercetin review
Treatment
SPRYCEL oral tablets (dasatinib alone), continuous dosing in cancer; supplemental quercetin in the review
Follow-up
Label version effective 15 September 2026
Study design
FDA prescribing information plus a risk-assessment review
Funding
not stated in the source

The label covers dasatinib alone in leukemia. Its safety rates come from continuous daily dosing and do not transfer to short senolytic courses. The quercetin statements come from the review, not the label.

Read the original source
9 people with diabetic kidney disease: fewer senescent cell markers, no control group

Clinical trial

Hickson LJ et al. EBioMedicine. 2019;47:446-456. PMID 31542391.

In 9 people with diabetic kidney disease (mean age 68.7 years, 2 women) given a short oral course of dasatinib plus quercetin, adipose tissue and skin biopsies taken before and 11 days after treatment showed fewer p16INK4A and p21CIP1-expressing cells, fewer cells with senescence-associated beta-galactosidase activity, fewer adipose macrophages, and lower circulating IL-1 alpha, IL-6, MMP-9 and MMP-12. There was no control group. The authors state that to date no peer-reviewed study had directly shown senolytics decrease senescent cells in humans before this report.

Participants / model
9 adults with diabetic kidney disease (mean age 68.7 years, 2 women; mean eGFR 27.0 mL/min/1.73 m2)
Treatment
Short oral course of dasatinib plus quercetin; doses and schedule not given on this page
Follow-up
Biopsies before and 11 days after treatment
Study design
Open-label phase 1 pilot with no control group (NCT02848131)
Funding
not stated in the source; Mayo Clinic holds patents on senolytic drugs, and an erratum was published in 2020

Nine people, open-label, no control: a biomarker signal, not an outcome result.

Read the original source

How is the combination meant to work, and how long do the drugs last?

D+Q is described as a senolytic combination that clears senescent cells. Dasatinib has a mean terminal half-life of 3 to 5 hours and is cleared mainly by CYP3A4. In 5 people with Alzheimer's disease dasatinib reached cerebrospinal fluid in 4 of 5 while quercetin was not detected, and no trial tested each drug alone, so each drug's contribution is unknown.

D+Q is described as a senolytic combination that clears senescent cells. In mice and human adipose explants it lowered the number of senescent cells, and in 9 people with diabetic kidney disease biopsies showed fewer senescent cell markers, in an open-label study with no control group.

Dasatinib's mean terminal half-life is 3 to 5 hours in the SPRYCEL label, and it is metabolized mainly by CYP3A4. The label says to avoid strong CYP3A4 inhibitors and grapefruit juice and not to give H2 antagonists or proton pump inhibitors with it. No pharmacokinetic data for quercetin appear in the sources reviewed.

In 5 people with Alzheimer's disease, dasatinib reached cerebrospinal fluid in 4 of 5 (CSF to plasma ratio 0.422 to 0.919%) while quercetin was not detected.

No comparator arms with quercetin alone or dasatinib alone were found in these trials, so the contribution of each drug is unknown.

SPRYCEL label, version 49 effective 15 September 2026: leukemia indications, warnings, PK

FDA prescribing information

DailyMed, U.S. National Library of Medicine. SPRYCEL (dasatinib) oral tablets, prescribing information, label version 49 effective 15 September 2026. Set ID 4764f37b-c9e6-4ede-bcc2-8a03b7c521df. The quercetin safety statements come from a German risk-assessment review (Andres 2018, PMID 29127724).

The label covers adults with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase, adults with chronic, accelerated or blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib, adults with Ph+ acute lymphoblastic leukemia (ALL) with resistance or intolerance to prior therapy, and pediatric patients 1 year and older with Ph+ CML in chronic phase or newly diagnosed Ph+ ALL with chemotherapy. Nothing in the label covers senescence or aging. The label lists no contraindications and warns of myelosuppression, bleeding (Grade 3 or 4 hemorrhage in 5.8% of adults, Grade 5 in 0.4%), fluid retention including pleural effusion (Grade 3 or 4 in 6% of adults with chronic phase CML on the labeled regimen, n = 548), cardiovascular toxicity (cardiac ischemic events 3.9% on dasatinib versus 1.6% on imatinib after 5 years in a newly diagnosed CML trial, n = 258), pulmonary arterial hypertension (stop if confirmed), QT prolongation, severe dermatologic reactions, tumor lysis, embryo-fetal toxicity and hepatotoxicity. The most common adverse reactions as a single agent (15% or more) were myelosuppression, fluid retention, diarrhea, headache, rash, hemorrhage, dyspnea, fatigue, nausea and musculoskeletal pain. Mean terminal half-life is 3 to 5 hours, metabolism is mainly CYP3A4 (avoid strong inhibitors and grapefruit juice), and the label says not to give H2 antagonists or proton pump inhibitors with it. These rates come from leukemia patients on daily dosing; senolytic trials use short intermittent courses, so the label rates do not carry over to those regimens. For quercetin, a German risk-assessment review found adverse effects rarely reported and mild in human studies, but no adequate data on long-term use (over 12 weeks) at intakes of 1000 mg or more, and animal signals for worsening damaged kidneys and promoting estrogen-dependent tumors, plus drug interactions.

Participants / model
Adults and children with Ph+ CML or Ph+ ALL in label studies; humans and animals in the quercetin review
Treatment
SPRYCEL oral tablets (dasatinib alone), continuous dosing in cancer; supplemental quercetin in the review
Follow-up
Label version effective 15 September 2026
Study design
FDA prescribing information plus a risk-assessment review
Funding
not stated in the source

The label covers dasatinib alone in leukemia. Its safety rates come from continuous daily dosing and do not transfer to short senolytic courses. The quercetin statements come from the review, not the label.

Read the original source
Alzheimer's pilots: 5 and 12 people, feasibility only, no appropriate control group

Clinical trial

Gonzales MM et al. Nat Med. 2023;29(10):2481-2488. PMID 37679434.

In 5 people with early symptomatic Alzheimer's disease who completed 12 weeks of D+Q, dasatinib reached cerebrospinal fluid in 4 of 5 (CSF to plasma ratio 0.422 to 0.919%) while quercetin was not detected, the treatment was well tolerated, and cognitive and imaging endpoints did not differ from baseline. In 12 older adults at risk of Alzheimer's disease who completed the study (about 10% of telephone-screened people completed), intermittent dasatinib plus quercetin over 12 weeks produced no related serious adverse events and a non-significant MoCA change of +1.0 point (95% CI -0.7 to 2.7); the authors state there was no appropriate control group and the data are preliminary.

Participants / model
5 adults with mild Alzheimer's disease; 12 older adults at risk of Alzheimer's disease
Treatment
Oral dasatinib plus quercetin for 12 weeks; doses and schedule not given on this page
Follow-up
12 weeks
Study design
Open-label phase 1 pilots
Funding
not stated in the source

Feasibility and tolerability only. The authors of the second pilot state there was no appropriate control group.

Read the original source
Origin of the claim: mice and human adipose explants, no living humans

Animal study

Xu M et al. Nat Med. 2018;24(8):1246-1256. PMID 29988130.

Transplanting small numbers of senescent cells into young mice caused persistent physical dysfunction and shortened survival. D+Q lowered the number of naturally occurring senescent cells and their secretion of frailty-related cytokines in explants of human adipose tissue. Intermittent oral senolytics given to senescent-cell-transplanted young mice and to naturally aged mice relieved physical dysfunction and increased post-treatment survival by 36%, with the mortality hazard cut to 65%.

Participants / model
Mice (young, old and senescent-cell-transplanted) and human adipose tissue explants; no living humans
Treatment
Intermittent oral dasatinib plus quercetin in mice, and explant exposure; dose not stated in the source
Follow-up
Intermittent; schedule not stated in the source
Study design
Animal and ex vivo study
Funding
not stated in the source; several authors hold a financial interest, including patents on senolytic drugs

Mouse and explant findings only. They cannot be read as an effect in people.

Read the original source
9 people with diabetic kidney disease: fewer senescent cell markers, no control group

Clinical trial

Hickson LJ et al. EBioMedicine. 2019;47:446-456. PMID 31542391.

In 9 people with diabetic kidney disease (mean age 68.7 years, 2 women) given a short oral course of dasatinib plus quercetin, adipose tissue and skin biopsies taken before and 11 days after treatment showed fewer p16INK4A and p21CIP1-expressing cells, fewer cells with senescence-associated beta-galactosidase activity, fewer adipose macrophages, and lower circulating IL-1 alpha, IL-6, MMP-9 and MMP-12. There was no control group. The authors state that to date no peer-reviewed study had directly shown senolytics decrease senescent cells in humans before this report.

Participants / model
9 adults with diabetic kidney disease (mean age 68.7 years, 2 women; mean eGFR 27.0 mL/min/1.73 m2)
Treatment
Short oral course of dasatinib plus quercetin; doses and schedule not given on this page
Follow-up
Biopsies before and 11 days after treatment
Study design
Open-label phase 1 pilot with no control group (NCT02848131)
Funding
not stated in the source; Mayo Clinic holds patents on senolytic drugs, and an erratum was published in 2020

Nine people, open-label, no control: a biomarker signal, not an outcome result.

Read the original source

What risks does the dasatinib label carry, and do they apply?

The dasatinib label lists no contraindications but warns of myelosuppression, bleeding, fluid retention, cardiovascular toxicity, pulmonary arterial hypertension, QT prolongation and hepatotoxicity, among others. Those rates come from continuous leukemia dosing and do not carry over to short senolytic courses, and adverse events were more frequent on D+Q than comparators in the trials that compared them.

The SPRYCEL label lists no contraindications and warns of myelosuppression, bleeding (Grade 3 or 4 hemorrhage in 5.8% of adults, Grade 5 in 0.4%), fluid retention including pleural effusion (Grade 3 or 4 in 6% of adults with chronic phase CML on the labeled regimen, n = 548), cardiovascular toxicity (cardiac ischemic events 3.9% on dasatinib versus 1.6% on imatinib after 5 years in a newly diagnosed CML trial, n = 258), pulmonary arterial hypertension (stop if confirmed), QT prolongation, severe dermatologic reactions, tumor lysis, embryo-fetal toxicity and hepatotoxicity. The most common adverse reactions as a single agent (15% or more) were myelosuppression, fluid retention, diarrhea, headache, rash, hemorrhage, dyspnea, fatigue, nausea and musculoskeletal pain.

These rates come from leukemia patients on continuous daily dosing. Senolytic trials use short intermittent courses, so the label rates do not carry over to those regimens, and the label's safety record is not a safety record for D+Q in healthy older adults. This page gives no dosing schedule.

In the trials that compared D+Q with a control, adverse events were more frequent on D+Q: 82% versus 43% in the fatty liver trial, 23 of 30 versus 5 of 30 other adverse events in the bone trial registry (open-label, no placebo, registry-posted and not peer reviewed), and 65 versus 22 overall non-serious adverse events in the randomized lung fibrosis pilot, fewer on placebo, with sleep disturbances and anxiety in 4 of 6 versus 0 of 6. The Alzheimer's pilots reported no related serious adverse events but had no or tiny control groups.

For quercetin, a German risk-assessment review (Andres 2018) found adverse effects rarely reported and mild in human studies, but no adequate data on long-term use (over 12 weeks) at intakes of 1000 mg or more, and animal signals for worsening damaged kidneys and promoting estrogen-dependent tumors, plus drug interactions.

Long-term (over 6 months) human safety of repeated D+Q courses was not found, and each drug's contribution to adverse events is unknown.

SPRYCEL label, version 49 effective 15 September 2026: leukemia indications, warnings, PK

FDA prescribing information

DailyMed, U.S. National Library of Medicine. SPRYCEL (dasatinib) oral tablets, prescribing information, label version 49 effective 15 September 2026. Set ID 4764f37b-c9e6-4ede-bcc2-8a03b7c521df. The quercetin safety statements come from a German risk-assessment review (Andres 2018, PMID 29127724).

The label covers adults with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase, adults with chronic, accelerated or blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib, adults with Ph+ acute lymphoblastic leukemia (ALL) with resistance or intolerance to prior therapy, and pediatric patients 1 year and older with Ph+ CML in chronic phase or newly diagnosed Ph+ ALL with chemotherapy. Nothing in the label covers senescence or aging. The label lists no contraindications and warns of myelosuppression, bleeding (Grade 3 or 4 hemorrhage in 5.8% of adults, Grade 5 in 0.4%), fluid retention including pleural effusion (Grade 3 or 4 in 6% of adults with chronic phase CML on the labeled regimen, n = 548), cardiovascular toxicity (cardiac ischemic events 3.9% on dasatinib versus 1.6% on imatinib after 5 years in a newly diagnosed CML trial, n = 258), pulmonary arterial hypertension (stop if confirmed), QT prolongation, severe dermatologic reactions, tumor lysis, embryo-fetal toxicity and hepatotoxicity. The most common adverse reactions as a single agent (15% or more) were myelosuppression, fluid retention, diarrhea, headache, rash, hemorrhage, dyspnea, fatigue, nausea and musculoskeletal pain. Mean terminal half-life is 3 to 5 hours, metabolism is mainly CYP3A4 (avoid strong inhibitors and grapefruit juice), and the label says not to give H2 antagonists or proton pump inhibitors with it. These rates come from leukemia patients on daily dosing; senolytic trials use short intermittent courses, so the label rates do not carry over to those regimens. For quercetin, a German risk-assessment review found adverse effects rarely reported and mild in human studies, but no adequate data on long-term use (over 12 weeks) at intakes of 1000 mg or more, and animal signals for worsening damaged kidneys and promoting estrogen-dependent tumors, plus drug interactions.

Participants / model
Adults and children with Ph+ CML or Ph+ ALL in label studies; humans and animals in the quercetin review
Treatment
SPRYCEL oral tablets (dasatinib alone), continuous dosing in cancer; supplemental quercetin in the review
Follow-up
Label version effective 15 September 2026
Study design
FDA prescribing information plus a risk-assessment review
Funding
not stated in the source

The label covers dasatinib alone in leukemia. Its safety rates come from continuous daily dosing and do not transfer to short senolytic courses. The quercetin statements come from the review, not the label.

Read the original source
Fibrotic MASH: 31 randomized, fibrosis improved in 47% versus 7%, online ahead of print

Randomized controlled trial

Koning M et al. Nat Metab. 2026. PMID 42823536.

A phase 2 double-blind placebo-controlled trial of 31 participants with fibrotic metabolic dysfunction-associated steatohepatitis (MASH; median age 56, 76% male, 58% with type 2 diabetes) gave D+Q or placebo in intermittent cycles. The primary endpoint, at least one stage of fibrosis improvement without MASH worsening on paired biopsies, was met in 47% on D+Q versus 7% on placebo (P = 0.02), MASH resolution was 53% versus 7% (P = 0.02), and adverse events were more frequent on D+Q (82% versus 43%) but all self-limiting. Separately, in a phase 1 pilot of 19 participants on a D+Q-based regimen for 6 months, epigenetic age acceleration rose significantly on first-generation and mitotic clocks at 3 and 6 months and telomere length fell, with no significant change on second- and third-generation clocks.

Participants / model
31 adults with fibrotic MASH; 19 participants in an epigenetic-clock pilot
Treatment
Oral dasatinib plus quercetin in intermittent cycles; D+Q for 6 months in the pilot, then D+Q plus fisetin for 6 months in its second phase; doses and schedule not given on this page
Follow-up
Repeated intermittent cycles (MASH trial); 6 months (pilot)
Study design
Phase 2 double-blind placebo-controlled randomized trial, online ahead of print as of 1 October 2026; and an uncontrolled phase 1 pilot
Funding
not stated in the source; several authors of the epigenetic-clock pilot are TruDiagnostic employees

No replication yet, and the abstract does not give a registry number (an Amsterdam UMC trial with matching design, NCT05506488, 30 participants, was seen but not matched). The epigenetic-clock pilot is uncontrolled.

Read the original source
Bone: 60 postmenopausal women, 20 weeks, primary endpoint not met

Randomized controlled trial

Farr JN et al. Nat Med. 2024;30(9):2605-2612. PMID 38956196.

In this phase 2 randomized trial of 60 postmenopausal women, intermittent D+Q did not change the primary endpoint, the bone resorption marker CTX at 20 weeks (median -4.1% on D+Q versus -7.7% in control; P = 0.611). The bone formation marker P1NP rose 16% relative to control at 2 weeks (P = 0.020) and at 4 weeks (P = 0.024) but was not different at 20 weeks, no serious adverse events were observed, and an exploratory subgroup with high T cell p16 mRNA showed a +2.7% radius bone mineral density change (P = 0.004). The registry describes a no-intervention control and open-label masking, and posts other adverse events in 23 of 30 on D+Q versus 5 of 30 controls (registry-posted, not peer reviewed).

Participants / model
60 postmenopausal women (the registry enrolled 74, including a fisetin arm)
Treatment
Oral dasatinib plus quercetin on an intermittent schedule over 20 weeks, versus no intervention; doses not given on this page
Follow-up
20 weeks
Study design
Phase 2 randomized open-label trial with a no-intervention control (NCT04313634)
Funding
not stated in the source; authors with patents on senolytics are listed

The adverse-event comparison from the registry is open-label with no placebo, and registry-posted figures are not peer reviewed.

Read the original source
Lung fibrosis: 14-patient open-label pilot, then a 12-patient randomized pilot with no meaningful difference

Randomized controlled trial

Nambiar A et al. EBioMedicine. 2023;90:104481. PMID 36857968.

In an open-label pilot of 14 patients with idiopathic pulmonary fibrosis given dasatinib plus quercetin in short intermittent courses, retention was 100%, one serious adverse event was reported, and 6-minute walk distance, gait speed and chair-stand time improved (p < .05) while pulmonary function was unchanged. In the follow-up randomized placebo-controlled pilot of 12 patients, all doses were taken, no serious adverse event was related to D+Q, physical, pulmonary and frailty measures did not appear to differ meaningfully between groups (under-powered), the abstract states the placebo arm reported fewer overall non-serious adverse events (65 versus 22), and sleep disturbances and anxiety occurred in 4 of 6 on D+Q versus 0 of 6 on placebo.

Participants / model
14 patients with idiopathic pulmonary fibrosis (open-label); 12 patients with idiopathic pulmonary fibrosis aged over 50 (randomized)
Treatment
Oral dasatinib plus quercetin in short intermittent courses over a few weeks; doses and schedule not given on this page
Follow-up
A few weeks of intermittent courses
Study design
Open-label pilot and randomized placebo-controlled pilot
Funding
not stated in the source; Mayo-linked authors hold senolytic patents

The randomized pilot was under-powered, and its adverse-event counts favor placebo.

Read the original source
Alzheimer's pilots: 5 and 12 people, feasibility only, no appropriate control group

Clinical trial

Gonzales MM et al. Nat Med. 2023;29(10):2481-2488. PMID 37679434.

In 5 people with early symptomatic Alzheimer's disease who completed 12 weeks of D+Q, dasatinib reached cerebrospinal fluid in 4 of 5 (CSF to plasma ratio 0.422 to 0.919%) while quercetin was not detected, the treatment was well tolerated, and cognitive and imaging endpoints did not differ from baseline. In 12 older adults at risk of Alzheimer's disease who completed the study (about 10% of telephone-screened people completed), intermittent dasatinib plus quercetin over 12 weeks produced no related serious adverse events and a non-significant MoCA change of +1.0 point (95% CI -0.7 to 2.7); the authors state there was no appropriate control group and the data are preliminary.

Participants / model
5 adults with mild Alzheimer's disease; 12 older adults at risk of Alzheimer's disease
Treatment
Oral dasatinib plus quercetin for 12 weeks; doses and schedule not given on this page
Follow-up
12 weeks
Study design
Open-label phase 1 pilots
Funding
not stated in the source

Feasibility and tolerability only. The authors of the second pilot state there was no appropriate control group.

Read the original source

Why does dasatinib plus quercetin sit in C tier?

C fits a prescription cancer drug plus a supplement used off label in short intermittent courses, with real mechanistic support but small and mixed human outcome data. Dasatinib's label safety data cover continuous leukemia dosing, not these regimens, and nothing studied is a healthy-aging outcome.

D+Q combines a prescription cancer drug with a supplement, used outside its labeled indications in short intermittent courses. The mechanism has real support: the mouse lifespan work, a 9-person biopsy study with fewer senescent cell markers, and a 31-person randomized fatty liver trial with a histology benefit.

The human outcome evidence is small and mixed: the bone trial missed its primary endpoint, the randomized lung fibrosis pilot showed no meaningful difference between groups, the cognition studies have no or tiny control groups, adverse events were more frequent on D+Q in the trials that compared them, and an epigenetic-clock pilot moved the wrong way. Dasatinib's label safety data are for continuous leukemia dosing, not these regimens, and nothing studied is a healthy-aging outcome.

The grade covers D+Q as discussed and used for senolytic purposes.

Origin of the claim: mice and human adipose explants, no living humans

Animal study

Xu M et al. Nat Med. 2018;24(8):1246-1256. PMID 29988130.

Transplanting small numbers of senescent cells into young mice caused persistent physical dysfunction and shortened survival. D+Q lowered the number of naturally occurring senescent cells and their secretion of frailty-related cytokines in explants of human adipose tissue. Intermittent oral senolytics given to senescent-cell-transplanted young mice and to naturally aged mice relieved physical dysfunction and increased post-treatment survival by 36%, with the mortality hazard cut to 65%.

Participants / model
Mice (young, old and senescent-cell-transplanted) and human adipose tissue explants; no living humans
Treatment
Intermittent oral dasatinib plus quercetin in mice, and explant exposure; dose not stated in the source
Follow-up
Intermittent; schedule not stated in the source
Study design
Animal and ex vivo study
Funding
not stated in the source; several authors hold a financial interest, including patents on senolytic drugs

Mouse and explant findings only. They cannot be read as an effect in people.

Read the original source
9 people with diabetic kidney disease: fewer senescent cell markers, no control group

Clinical trial

Hickson LJ et al. EBioMedicine. 2019;47:446-456. PMID 31542391.

In 9 people with diabetic kidney disease (mean age 68.7 years, 2 women) given a short oral course of dasatinib plus quercetin, adipose tissue and skin biopsies taken before and 11 days after treatment showed fewer p16INK4A and p21CIP1-expressing cells, fewer cells with senescence-associated beta-galactosidase activity, fewer adipose macrophages, and lower circulating IL-1 alpha, IL-6, MMP-9 and MMP-12. There was no control group. The authors state that to date no peer-reviewed study had directly shown senolytics decrease senescent cells in humans before this report.

Participants / model
9 adults with diabetic kidney disease (mean age 68.7 years, 2 women; mean eGFR 27.0 mL/min/1.73 m2)
Treatment
Short oral course of dasatinib plus quercetin; doses and schedule not given on this page
Follow-up
Biopsies before and 11 days after treatment
Study design
Open-label phase 1 pilot with no control group (NCT02848131)
Funding
not stated in the source; Mayo Clinic holds patents on senolytic drugs, and an erratum was published in 2020

Nine people, open-label, no control: a biomarker signal, not an outcome result.

Read the original source
Fibrotic MASH: 31 randomized, fibrosis improved in 47% versus 7%, online ahead of print

Randomized controlled trial

Koning M et al. Nat Metab. 2026. PMID 42823536.

A phase 2 double-blind placebo-controlled trial of 31 participants with fibrotic metabolic dysfunction-associated steatohepatitis (MASH; median age 56, 76% male, 58% with type 2 diabetes) gave D+Q or placebo in intermittent cycles. The primary endpoint, at least one stage of fibrosis improvement without MASH worsening on paired biopsies, was met in 47% on D+Q versus 7% on placebo (P = 0.02), MASH resolution was 53% versus 7% (P = 0.02), and adverse events were more frequent on D+Q (82% versus 43%) but all self-limiting. Separately, in a phase 1 pilot of 19 participants on a D+Q-based regimen for 6 months, epigenetic age acceleration rose significantly on first-generation and mitotic clocks at 3 and 6 months and telomere length fell, with no significant change on second- and third-generation clocks.

Participants / model
31 adults with fibrotic MASH; 19 participants in an epigenetic-clock pilot
Treatment
Oral dasatinib plus quercetin in intermittent cycles; D+Q for 6 months in the pilot, then D+Q plus fisetin for 6 months in its second phase; doses and schedule not given on this page
Follow-up
Repeated intermittent cycles (MASH trial); 6 months (pilot)
Study design
Phase 2 double-blind placebo-controlled randomized trial, online ahead of print as of 1 October 2026; and an uncontrolled phase 1 pilot
Funding
not stated in the source; several authors of the epigenetic-clock pilot are TruDiagnostic employees

No replication yet, and the abstract does not give a registry number (an Amsterdam UMC trial with matching design, NCT05506488, 30 participants, was seen but not matched). The epigenetic-clock pilot is uncontrolled.

Read the original source
Bone: 60 postmenopausal women, 20 weeks, primary endpoint not met

Randomized controlled trial

Farr JN et al. Nat Med. 2024;30(9):2605-2612. PMID 38956196.

In this phase 2 randomized trial of 60 postmenopausal women, intermittent D+Q did not change the primary endpoint, the bone resorption marker CTX at 20 weeks (median -4.1% on D+Q versus -7.7% in control; P = 0.611). The bone formation marker P1NP rose 16% relative to control at 2 weeks (P = 0.020) and at 4 weeks (P = 0.024) but was not different at 20 weeks, no serious adverse events were observed, and an exploratory subgroup with high T cell p16 mRNA showed a +2.7% radius bone mineral density change (P = 0.004). The registry describes a no-intervention control and open-label masking, and posts other adverse events in 23 of 30 on D+Q versus 5 of 30 controls (registry-posted, not peer reviewed).

Participants / model
60 postmenopausal women (the registry enrolled 74, including a fisetin arm)
Treatment
Oral dasatinib plus quercetin on an intermittent schedule over 20 weeks, versus no intervention; doses not given on this page
Follow-up
20 weeks
Study design
Phase 2 randomized open-label trial with a no-intervention control (NCT04313634)
Funding
not stated in the source; authors with patents on senolytics are listed

The adverse-event comparison from the registry is open-label with no placebo, and registry-posted figures are not peer reviewed.

Read the original source
Lung fibrosis: 14-patient open-label pilot, then a 12-patient randomized pilot with no meaningful difference

Randomized controlled trial

Nambiar A et al. EBioMedicine. 2023;90:104481. PMID 36857968.

In an open-label pilot of 14 patients with idiopathic pulmonary fibrosis given dasatinib plus quercetin in short intermittent courses, retention was 100%, one serious adverse event was reported, and 6-minute walk distance, gait speed and chair-stand time improved (p < .05) while pulmonary function was unchanged. In the follow-up randomized placebo-controlled pilot of 12 patients, all doses were taken, no serious adverse event was related to D+Q, physical, pulmonary and frailty measures did not appear to differ meaningfully between groups (under-powered), the abstract states the placebo arm reported fewer overall non-serious adverse events (65 versus 22), and sleep disturbances and anxiety occurred in 4 of 6 on D+Q versus 0 of 6 on placebo.

Participants / model
14 patients with idiopathic pulmonary fibrosis (open-label); 12 patients with idiopathic pulmonary fibrosis aged over 50 (randomized)
Treatment
Oral dasatinib plus quercetin in short intermittent courses over a few weeks; doses and schedule not given on this page
Follow-up
A few weeks of intermittent courses
Study design
Open-label pilot and randomized placebo-controlled pilot
Funding
not stated in the source; Mayo-linked authors hold senolytic patents

The randomized pilot was under-powered, and its adverse-event counts favor placebo.

Read the original source
Alzheimer's pilots: 5 and 12 people, feasibility only, no appropriate control group

Clinical trial

Gonzales MM et al. Nat Med. 2023;29(10):2481-2488. PMID 37679434.

In 5 people with early symptomatic Alzheimer's disease who completed 12 weeks of D+Q, dasatinib reached cerebrospinal fluid in 4 of 5 (CSF to plasma ratio 0.422 to 0.919%) while quercetin was not detected, the treatment was well tolerated, and cognitive and imaging endpoints did not differ from baseline. In 12 older adults at risk of Alzheimer's disease who completed the study (about 10% of telephone-screened people completed), intermittent dasatinib plus quercetin over 12 weeks produced no related serious adverse events and a non-significant MoCA change of +1.0 point (95% CI -0.7 to 2.7); the authors state there was no appropriate control group and the data are preliminary.

Participants / model
5 adults with mild Alzheimer's disease; 12 older adults at risk of Alzheimer's disease
Treatment
Oral dasatinib plus quercetin for 12 weeks; doses and schedule not given on this page
Follow-up
12 weeks
Study design
Open-label phase 1 pilots
Funding
not stated in the source

Feasibility and tolerability only. The authors of the second pilot state there was no appropriate control group.

Read the original source
SPRYCEL label, version 49 effective 15 September 2026: leukemia indications, warnings, PK

FDA prescribing information

DailyMed, U.S. National Library of Medicine. SPRYCEL (dasatinib) oral tablets, prescribing information, label version 49 effective 15 September 2026. Set ID 4764f37b-c9e6-4ede-bcc2-8a03b7c521df. The quercetin safety statements come from a German risk-assessment review (Andres 2018, PMID 29127724).

The label covers adults with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase, adults with chronic, accelerated or blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib, adults with Ph+ acute lymphoblastic leukemia (ALL) with resistance or intolerance to prior therapy, and pediatric patients 1 year and older with Ph+ CML in chronic phase or newly diagnosed Ph+ ALL with chemotherapy. Nothing in the label covers senescence or aging. The label lists no contraindications and warns of myelosuppression, bleeding (Grade 3 or 4 hemorrhage in 5.8% of adults, Grade 5 in 0.4%), fluid retention including pleural effusion (Grade 3 or 4 in 6% of adults with chronic phase CML on the labeled regimen, n = 548), cardiovascular toxicity (cardiac ischemic events 3.9% on dasatinib versus 1.6% on imatinib after 5 years in a newly diagnosed CML trial, n = 258), pulmonary arterial hypertension (stop if confirmed), QT prolongation, severe dermatologic reactions, tumor lysis, embryo-fetal toxicity and hepatotoxicity. The most common adverse reactions as a single agent (15% or more) were myelosuppression, fluid retention, diarrhea, headache, rash, hemorrhage, dyspnea, fatigue, nausea and musculoskeletal pain. Mean terminal half-life is 3 to 5 hours, metabolism is mainly CYP3A4 (avoid strong inhibitors and grapefruit juice), and the label says not to give H2 antagonists or proton pump inhibitors with it. These rates come from leukemia patients on daily dosing; senolytic trials use short intermittent courses, so the label rates do not carry over to those regimens. For quercetin, a German risk-assessment review found adverse effects rarely reported and mild in human studies, but no adequate data on long-term use (over 12 weeks) at intakes of 1000 mg or more, and animal signals for worsening damaged kidneys and promoting estrogen-dependent tumors, plus drug interactions.

Participants / model
Adults and children with Ph+ CML or Ph+ ALL in label studies; humans and animals in the quercetin review
Treatment
SPRYCEL oral tablets (dasatinib alone), continuous dosing in cancer; supplemental quercetin in the review
Follow-up
Label version effective 15 September 2026
Study design
FDA prescribing information plus a risk-assessment review
Funding
not stated in the source

The label covers dasatinib alone in leukemia. Its safety rates come from continuous daily dosing and do not transfer to short senolytic courses. The quercetin statements come from the review, not the label.

Read the original source

Studies and sources

PubChem: dasatinib and quercetin are two separate agents; no combined product

Chemical identity record

National Library of Medicine. PubChem compound records CID 3062316 (dasatinib) and CID 5280343 (quercetin). openFDA Drugs@FDA and DailyMed drug-name searches for quercetin run on 11 October 2026.

Dasatinib: PubChem CID 3062316, C22H26ClN7O2S, 488.0 g/mol, CAS 302962-49-8, with Sprycel among the listed synonyms. Quercetin: CID 5280343, C15H10O7, 302.23 g/mol, CAS 117-39-5. There is no combined product: dasatinib is a prescription kinase inhibitor and quercetin is a flavonol taken as a supplement. Trial quercetin products and amounts vary, including a phytosome product, so doses and products do not transfer between studies. On 11 October 2026 an openFDA Drugs@FDA query for quercetin returned no match, and a DailyMed drug-name search returned only homeopathic and similar multi-ingredient listings that contain quercetin, with no single-ingredient quercetin drug label.

Participants / model
Chemical identity, not a clinical population
Treatment
Defined molecules; separate products
Follow-up
Searches run on 11 October 2026
Study design
NLM chemical records plus dated US approval-record search
Funding
not stated in the source

Identity records only; they say nothing about efficacy or safety.

Read the original source
SPRYCEL label, version 49 effective 15 September 2026: leukemia indications, warnings, PK

FDA prescribing information

DailyMed, U.S. National Library of Medicine. SPRYCEL (dasatinib) oral tablets, prescribing information, label version 49 effective 15 September 2026. Set ID 4764f37b-c9e6-4ede-bcc2-8a03b7c521df. The quercetin safety statements come from a German risk-assessment review (Andres 2018, PMID 29127724).

The label covers adults with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase, adults with chronic, accelerated or blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib, adults with Ph+ acute lymphoblastic leukemia (ALL) with resistance or intolerance to prior therapy, and pediatric patients 1 year and older with Ph+ CML in chronic phase or newly diagnosed Ph+ ALL with chemotherapy. Nothing in the label covers senescence or aging. The label lists no contraindications and warns of myelosuppression, bleeding (Grade 3 or 4 hemorrhage in 5.8% of adults, Grade 5 in 0.4%), fluid retention including pleural effusion (Grade 3 or 4 in 6% of adults with chronic phase CML on the labeled regimen, n = 548), cardiovascular toxicity (cardiac ischemic events 3.9% on dasatinib versus 1.6% on imatinib after 5 years in a newly diagnosed CML trial, n = 258), pulmonary arterial hypertension (stop if confirmed), QT prolongation, severe dermatologic reactions, tumor lysis, embryo-fetal toxicity and hepatotoxicity. The most common adverse reactions as a single agent (15% or more) were myelosuppression, fluid retention, diarrhea, headache, rash, hemorrhage, dyspnea, fatigue, nausea and musculoskeletal pain. Mean terminal half-life is 3 to 5 hours, metabolism is mainly CYP3A4 (avoid strong inhibitors and grapefruit juice), and the label says not to give H2 antagonists or proton pump inhibitors with it. These rates come from leukemia patients on daily dosing; senolytic trials use short intermittent courses, so the label rates do not carry over to those regimens. For quercetin, a German risk-assessment review found adverse effects rarely reported and mild in human studies, but no adequate data on long-term use (over 12 weeks) at intakes of 1000 mg or more, and animal signals for worsening damaged kidneys and promoting estrogen-dependent tumors, plus drug interactions.

Participants / model
Adults and children with Ph+ CML or Ph+ ALL in label studies; humans and animals in the quercetin review
Treatment
SPRYCEL oral tablets (dasatinib alone), continuous dosing in cancer; supplemental quercetin in the review
Follow-up
Label version effective 15 September 2026
Study design
FDA prescribing information plus a risk-assessment review
Funding
not stated in the source

The label covers dasatinib alone in leukemia. Its safety rates come from continuous daily dosing and do not transfer to short senolytic courses. The quercetin statements come from the review, not the label.

Read the original source
Drugs@FDA: SPRYCEL approved 28 June 2006; PHYRAGO original approval 5 December 2023

Regulatory record

U.S. Food and Drug Administration. Drugs@FDA application record for NDA 021986 (SPRYCEL), with related dasatinib application NDA 216099 (PHYRAGO). Dates read from the openFDA Drugs@FDA records.

FDA first approved SPRYCEL under NDA 021986 on 28 June 2006 (Bristol Myers Squibb). A later application, PHYRAGO, is NDA 216099 with an original approval date of 5 December 2023, and several generic dasatinib applications are listed.

Participants / model
Not a clinical population
Treatment
Drug applications
Follow-up
Approvals from 2006 to 2023
Study design
FDA application records
Funding
not stated in the source

These records give approval dates. Indications come from the product label.

Read the original source
Origin of the claim: mice and human adipose explants, no living humans

Animal study

Xu M et al. Nat Med. 2018;24(8):1246-1256. PMID 29988130.

Transplanting small numbers of senescent cells into young mice caused persistent physical dysfunction and shortened survival. D+Q lowered the number of naturally occurring senescent cells and their secretion of frailty-related cytokines in explants of human adipose tissue. Intermittent oral senolytics given to senescent-cell-transplanted young mice and to naturally aged mice relieved physical dysfunction and increased post-treatment survival by 36%, with the mortality hazard cut to 65%.

Participants / model
Mice (young, old and senescent-cell-transplanted) and human adipose tissue explants; no living humans
Treatment
Intermittent oral dasatinib plus quercetin in mice, and explant exposure; dose not stated in the source
Follow-up
Intermittent; schedule not stated in the source
Study design
Animal and ex vivo study
Funding
not stated in the source; several authors hold a financial interest, including patents on senolytic drugs

Mouse and explant findings only. They cannot be read as an effect in people.

Read the original source
9 people with diabetic kidney disease: fewer senescent cell markers, no control group

Clinical trial

Hickson LJ et al. EBioMedicine. 2019;47:446-456. PMID 31542391.

In 9 people with diabetic kidney disease (mean age 68.7 years, 2 women) given a short oral course of dasatinib plus quercetin, adipose tissue and skin biopsies taken before and 11 days after treatment showed fewer p16INK4A and p21CIP1-expressing cells, fewer cells with senescence-associated beta-galactosidase activity, fewer adipose macrophages, and lower circulating IL-1 alpha, IL-6, MMP-9 and MMP-12. There was no control group. The authors state that to date no peer-reviewed study had directly shown senolytics decrease senescent cells in humans before this report.

Participants / model
9 adults with diabetic kidney disease (mean age 68.7 years, 2 women; mean eGFR 27.0 mL/min/1.73 m2)
Treatment
Short oral course of dasatinib plus quercetin; doses and schedule not given on this page
Follow-up
Biopsies before and 11 days after treatment
Study design
Open-label phase 1 pilot with no control group (NCT02848131)
Funding
not stated in the source; Mayo Clinic holds patents on senolytic drugs, and an erratum was published in 2020

Nine people, open-label, no control: a biomarker signal, not an outcome result.

Read the original source
Lung fibrosis: 14-patient open-label pilot, then a 12-patient randomized pilot with no meaningful difference

Randomized controlled trial

Nambiar A et al. EBioMedicine. 2023;90:104481. PMID 36857968.

In an open-label pilot of 14 patients with idiopathic pulmonary fibrosis given dasatinib plus quercetin in short intermittent courses, retention was 100%, one serious adverse event was reported, and 6-minute walk distance, gait speed and chair-stand time improved (p < .05) while pulmonary function was unchanged. In the follow-up randomized placebo-controlled pilot of 12 patients, all doses were taken, no serious adverse event was related to D+Q, physical, pulmonary and frailty measures did not appear to differ meaningfully between groups (under-powered), the abstract states the placebo arm reported fewer overall non-serious adverse events (65 versus 22), and sleep disturbances and anxiety occurred in 4 of 6 on D+Q versus 0 of 6 on placebo.

Participants / model
14 patients with idiopathic pulmonary fibrosis (open-label); 12 patients with idiopathic pulmonary fibrosis aged over 50 (randomized)
Treatment
Oral dasatinib plus quercetin in short intermittent courses over a few weeks; doses and schedule not given on this page
Follow-up
A few weeks of intermittent courses
Study design
Open-label pilot and randomized placebo-controlled pilot
Funding
not stated in the source; Mayo-linked authors hold senolytic patents

The randomized pilot was under-powered, and its adverse-event counts favor placebo.

Read the original source
Alzheimer's pilots: 5 and 12 people, feasibility only, no appropriate control group

Clinical trial

Gonzales MM et al. Nat Med. 2023;29(10):2481-2488. PMID 37679434.

In 5 people with early symptomatic Alzheimer's disease who completed 12 weeks of D+Q, dasatinib reached cerebrospinal fluid in 4 of 5 (CSF to plasma ratio 0.422 to 0.919%) while quercetin was not detected, the treatment was well tolerated, and cognitive and imaging endpoints did not differ from baseline. In 12 older adults at risk of Alzheimer's disease who completed the study (about 10% of telephone-screened people completed), intermittent dasatinib plus quercetin over 12 weeks produced no related serious adverse events and a non-significant MoCA change of +1.0 point (95% CI -0.7 to 2.7); the authors state there was no appropriate control group and the data are preliminary.

Participants / model
5 adults with mild Alzheimer's disease; 12 older adults at risk of Alzheimer's disease
Treatment
Oral dasatinib plus quercetin for 12 weeks; doses and schedule not given on this page
Follow-up
12 weeks
Study design
Open-label phase 1 pilots
Funding
not stated in the source

Feasibility and tolerability only. The authors of the second pilot state there was no appropriate control group.

Read the original source
Bone: 60 postmenopausal women, 20 weeks, primary endpoint not met

Randomized controlled trial

Farr JN et al. Nat Med. 2024;30(9):2605-2612. PMID 38956196.

In this phase 2 randomized trial of 60 postmenopausal women, intermittent D+Q did not change the primary endpoint, the bone resorption marker CTX at 20 weeks (median -4.1% on D+Q versus -7.7% in control; P = 0.611). The bone formation marker P1NP rose 16% relative to control at 2 weeks (P = 0.020) and at 4 weeks (P = 0.024) but was not different at 20 weeks, no serious adverse events were observed, and an exploratory subgroup with high T cell p16 mRNA showed a +2.7% radius bone mineral density change (P = 0.004). The registry describes a no-intervention control and open-label masking, and posts other adverse events in 23 of 30 on D+Q versus 5 of 30 controls (registry-posted, not peer reviewed).

Participants / model
60 postmenopausal women (the registry enrolled 74, including a fisetin arm)
Treatment
Oral dasatinib plus quercetin on an intermittent schedule over 20 weeks, versus no intervention; doses not given on this page
Follow-up
20 weeks
Study design
Phase 2 randomized open-label trial with a no-intervention control (NCT04313634)
Funding
not stated in the source; authors with patents on senolytics are listed

The adverse-event comparison from the registry is open-label with no placebo, and registry-posted figures are not peer reviewed.

Read the original source
Fibrotic MASH: 31 randomized, fibrosis improved in 47% versus 7%, online ahead of print

Randomized controlled trial

Koning M et al. Nat Metab. 2026. PMID 42823536.

A phase 2 double-blind placebo-controlled trial of 31 participants with fibrotic metabolic dysfunction-associated steatohepatitis (MASH; median age 56, 76% male, 58% with type 2 diabetes) gave D+Q or placebo in intermittent cycles. The primary endpoint, at least one stage of fibrosis improvement without MASH worsening on paired biopsies, was met in 47% on D+Q versus 7% on placebo (P = 0.02), MASH resolution was 53% versus 7% (P = 0.02), and adverse events were more frequent on D+Q (82% versus 43%) but all self-limiting. Separately, in a phase 1 pilot of 19 participants on a D+Q-based regimen for 6 months, epigenetic age acceleration rose significantly on first-generation and mitotic clocks at 3 and 6 months and telomere length fell, with no significant change on second- and third-generation clocks.

Participants / model
31 adults with fibrotic MASH; 19 participants in an epigenetic-clock pilot
Treatment
Oral dasatinib plus quercetin in intermittent cycles; D+Q for 6 months in the pilot, then D+Q plus fisetin for 6 months in its second phase; doses and schedule not given on this page
Follow-up
Repeated intermittent cycles (MASH trial); 6 months (pilot)
Study design
Phase 2 double-blind placebo-controlled randomized trial, online ahead of print as of 1 October 2026; and an uncontrolled phase 1 pilot
Funding
not stated in the source; several authors of the epigenetic-clock pilot are TruDiagnostic employees

No replication yet, and the abstract does not give a registry number (an Amsterdam UMC trial with matching design, NCT05506488, 30 participants, was seen but not matched). The epigenetic-clock pilot is uncontrolled.

Read the original source

Why is Dasatinib plus quercetin in C tier?

C fits a prescription cancer drug plus a supplement used off label in short intermittent courses, with real mechanistic support but small and mixed human outcome data. The bone trial missed its primary endpoint, the randomized lung fibrosis pilot showed no meaningful difference, adverse events were more frequent on D+Q where compared, and dasatinib's label safety data cover continuous leukemia dosing, not these regimens. The newest randomized result, in fatty liver disease, is positive but unreplicated, and nothing studied is a healthy-aging outcome.